focu becom premier research-intens biopharmaceut compani
maintain buy rate upgrad tp
previous deriv tp base
estim ep forward price-to-earnings multipl
give upsid potenti
expect top-lin revenu grow
estim base follow factor strong
growth oncolog vaccin hospit specialti well
anim health balanc capit alloc strong
invest develop pipelin
result bolster confid merck innovation-
base strategi key pillar oncolog vaccin
anim health select hospit specialti care product
expect drive sustain growth long-term
merck deliv strong perform year
growth revenu
estim expect growth
revenu growth base merck
expect continu growth oncolog vaccin
hospit specialti anim health busi
adjust ep increas in-lin
estim ep increas
reflect charg relat
format strateg oncolog collabor eisai co
mn except ep
compani namemerck compani inc tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric apr week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha merck compani inc april
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
sale includ replenish
dose gardasil borrow
center diseas control prevent pediatr
vaccin stockpil borrow reduc sale
pharmaceut sale increas
reflect growth oncolog vaccin hospit acut
care partial off-set declin virolog loss
market exclus sever product
anim sale increas
sale growth driven sale increas
companion anim product bravecto fluralan
line product kill flea tick dog cat
week companion anim vaccin
sale growth also driven higher sale livestock
product includ rumin poultri swine product
decemb merck announc acquir
privat held antelliq group establish merck
anim health leader digit anim identif
traceabl monitor solut one fastest
grow part anim health industri
current price-to-earnings
due increas stock price price-to-earnings
volatil till may later surg due strong
growth ep stock price averag price-to-earnings
expect forward price-to-earnings
multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date last split factor new per last split date feb inform merck compani inc april
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur merger acquisition- total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli merck compani inc april
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item merck compani inc april
provid oper activ compar
provid invest activ compar increas
cash provid invest activ driven lower purchas secur invest
use financ activ compar increas
cash use financ activ driven higher purchas treasuri stock higher payment
debt payment conting consider relat prior year busi acquisit partial off-set
increas short-term borrow
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end merck compani inc april
merck deliv strong perform year due growth oncolog
vaccin hospit acut care anim health
total sale increas compar
includ neg impact foreign exchang total sale
 increas compar
total intern sale increas
compar
gaap sale declin compar
non-gaap cost sale increas
compar
gross margin compar
increas driven part lower acquisit divestiture-rel cost
restructur cost
non-gaap gross margin compar
increas gross margin reflect favor effect product
mix cost record relat cyber-attack partial off-set
unfavor effect price pressur amort amount
capit potenti futur mileston payment relat collabor
sg expens flat compar non-
sg expens compar
 expens declin compar
decreas due lower expens relat busi
develop activ lower in-process research develop ipr
impair charg partial off-set higher clinic develop spend
particular oncolog collabor invest discoveri earli
drug develop non-gaap expens increas
compar
total sale increas
compar
neg impact
 expens declin
compar
incom expens net expens compar
incom incom expens net
reflect goodwil impair charg well recognit unreal
loss secur result adopt new account standard
invest equiti secur
non-gaap incom expens net compar
non-gaap incom expens net fourth
quarter reflect recognit unreal loss secur
result adopt new account standard invest equiti
restructur cost declin compar
effect tax rate compar
effect incom tax rate reflect unfavor
impact adjust provision amount record prior year
associ enact tax legisl includ relat
transit tax non-gaap effect incom tax rate
compar
net incom compar net loss
non-gaap net incom compar
gaap ep compar non-
gaap ep compar
net
expens
compar
incom
gaap ep
compar
non-
gaap ep
compar
total revenu increas compar
sale includ replenish dose
vaccin prevent certain cancer diseas caus human
papillomaviru hpv borrow center diseas
control prevent pediatr vaccin stockpil
sale unit state increas compar
increas driven higher sale keytruda
gardasil/gardasil nuvar bridion well allianc revenu
lynparza lenvima higher sale anim health product
total intern sale increas compar
increas reflect growth keytruda gardasil/gardasil
januvia janumet atozet well higher sale anim health product
cog increas compar
cost includ charg relat termin collabor
agreement samsung bioepi co ltd samsung insulin glargin
compar
increas
compar
merck record cumul amort expens
amount capit connect recognit liabil potenti
futur mileston payment relat collabor
sale includ expens amort intang asset
record connect busi acquisit total
non-gaap cost sale increas compar
gross margin compar y/i
improv gross margin reflect lower net impact amort
intang asset intang asset impair charg relat busi
acquisit well restructur cost
gross margin improv also reflect favor effect
product mix amort unfavor manufactur varianc record
result part june cyber-attack
margin
compar
non-gaap gross margin compar
decreas non-gaap gross margin reflect unfavor effect
amort amount capit potenti futur mileston payment
relat collabor price pressur partial off-set favor
effect product mix cost record relat cyber-attack
compar
sg expens flat compar reflect
higher administr cost unfavor effect foreign exchang
off-set lower sell promot expens non-gaap sg expens
compar reflect higher
administr cost unfavor effect foreign exchang off-set
lower sell promot cost
 expens decreas compar
non-gaap expens increas
compar increas reflect higher clinic
develop spend invest discoveri earli drug
develop partial off-set lower busi develop cost
restructur cost declin compar
incom expens net incom
compar incom non-gaap incom
expens net incom compar incom
tax rate compar
effect incom tax rate reflect unfavor impact charg
relat format collabor eisai tax benefit
recogn non-gaap tax rate compar
gaap ep increas
compar
compar
net incom increas compar
non-gaap net incom increas compar
gaap ep increas compar non-
gaap ep increas compar
merck oper two busi segment pharmaceut anim
segment includ human health pharmaceut
vaccin product health pharmaceut product consist
therapeut prevent agent gener sold prescript
treatment human disord vaccin product consist prevent
pediatr adolesc adult vaccin primarili administ physician
pharmaceut segment revenu increas
compar includ neg impact
foreign exchang total revenu increas
compar
increas driven growth oncolog vaccin partial off-set
lower sale virolog on-going impact loss market
exclus sever product
total revenu pharmaceut segment increas
compar total intern
revenu increas compar
growth oncolog driven signific increas sale
keytruda reflect strong momentum treatment patient
nsclc merck continu launch new indic global
oncolog sale reflect allianc revenu relat lenvima
relat lynparza repres merck share profit
product sale net cost sale commerci cost
total revenu keytruda increas
compar total revenu increas
compar
total revenu keytruda increas
compar total intern revenu
increas compar
allianc revenu lynparza compar
total revenu increas compar
allianc revenu lenvima
total revenu total intern
revenu
emend revenu declin compar
total revenu declin
compar
temodar revenu declin compar
total revenu declin
compar
total revenu
keytruda increas
compar
allianc revenu
lenvima
growth vaccin driven increas sale gardasil
gardasil due on-going commerci launch china well
growth unit state europ increas sale
reflect time public sector purchas
increas
compar
growth vaccin partial off-set signific decreas sale
zostavax due compet product receiv preferenti
recommend advisori committe immun
practic octob compani anticip futur sale
zostavax continu unfavor affect competit
increas
compar
gardasil revenu increas compar
total revenu increas
compar
gardasil revenu form increas
compar revenu increas
compar
proquad/m-m-r ii /varivax revenu increas
compar total revenu increas
compar
proquad/m-m-r ii /varivax revenu increas
compar revenu
increas compar
rotateq revenu increas compar
total revenu increas
compar
rotateq revenu increas
compar total intern revenu increas
compar
zostavax revenu declin compar
total revenu declin
compar
zostavax revenu declin
compar total intern revenu declin
compar
pneumovax revenu increas
compar total revenu increas
compar
pneumovax revenu increas
compar total intern revenu increas
compar
perform hospit acut care reflect strong demand
bridion sugammadex inject mg/ml on-going launch
bridion revenu increas compar
total revenu increas
compar
bridion revenu increas
compar total intern revenu decreas
compar
noxafil revenu increas compar
total revenu increas
compar
compar
compar
noxafil revenu increas
compar revenu increas
compar
noxafil revenu
 increas
compar
invanz revenu decreas compar
total revenu decreas
compar
invanz revenu declin
compar total intern revenu declin
compar
declin
compar
cancida revenu declin compar
total revenu declin
compar
cancida revenu declin
compar total intern revenu declin
compar
simponi revenu increas compar
total revenu increas
compar
remicad revenu declin compar
total revenu declin
compar
total revenu isentress isentress hd decreas
compar total revenu
decreas compar
total revenu
decreas
compar
isentress/isentress hd revenu declin
compar total intern revenu
decreas compar
zepati revenu decreas compar
total revenu declin
compar
zepati revenu declin
compar total intern revenu declin
compar
januvia janumet
medicin help lower
blood sugar level adult
type diabet
combin global sale zetia market countri outsid
unit state ezetrol vytorin market outsid unit state
inegi well atozet rosuzet market certain countri
outsid unit state declin
compar includ favor effect foreign exchang
sale declin driven lower demand unit state
world-wide combin sale januvia janumet medicin help
lower blood sugar level adult type diabet
essenti flat compar foreign exchang favor
affect sale perform sale perform
period driven on-going price pressur particularli
unit state partial off-set higher demand intern
world-wide sale nuvar increas
compar total revenu increas
compar sale growth driven
higher price unit state patent provid market
exclus nuvar expir april merck anticip
signific declin
nuvar revenu increas
compar total intern revenu declin
compar
implanon nexplanon revenu decreas
compar total revenu increas
compar
implanon nexplanon revenu increas
compar total intern revenu increas
compar
total revenu diversifi brand decreas
compar total revenu declin
compar
total revenu compar
total intern revenu compar
world-wide sale
nuvar increas
compar
total revenu
decreas
compar
anim segment includ pharmaceut vaccin product
prevent treatment control diseas major farm
anim sale increas compar
total revenu increas
compar
anim revenu increas
compar total intern revenu increas
compar
total revenu livestock increas
compar total revenu increas
compar
livestock revenu increas
compar total intern revenu decreas
compar
total revenu companion anim increas
compar total revenu increas
compar
total revenu compar
total intern revenu increas
compar
increas
compar
total revenu
increas
compar
oncolog pipelin highlight merck continu advanc develop
program keytruda pembrolizumab compani therapi
lynparza olaparib parp inhibitor co-develop co-
commerci astrazeneca lenvima lenvatinib mesyl oral
avail tyrosin kinas inhibitor co-develop co-commerci
eisai
merck present data pivot phase trial studi
keytruda combin axitinib patient advanc metastat
renal cell carcinoma annual american societi clinic oncolog
genitourinari cancer symposium san francisco oral session
merck announc food drug administr fda
approv keytruda follow indic
merck announc
 food drug
treatment
patient
carcinoma
previous treat
sorafenib
combin carboplatin either paclitaxel nab-paclitaxel
first-lin treatment patient metastat squamou non-smal cell
lung cancer nsclc make first approv first-lin
treatment squamou nsclc regardless express approv
base result trial
treatment patient hepatocellular carcinoma
previous treat sorafenib
treatment adult pediatr patient recurr local
advanc metastat merkel cell carcinoma
merck announc five new approv includ three expand use
advanc nsclc one adjuv melanoma well new indic
advanc microsatellit instability-high msi-h tumor grant
merck announc
approv keytruda
adjuv treatment
adult stage
melanoma lymph node
involv
resect base data
pivot phase
merck announc european commiss ec approv keytruda
adjuv treatment adult stage melanoma lymph
node involv undergon complet resect base data
pivot phase trial
merck announc result phase trial investig
keytruda monotherapi second-lin treatment advanc
metastat esophag esophagogastr junction carcinoma
demonstr reduct risk death compar
chemotherapi previous treat patient advanc esophag
merck announc fda extend action date
supplement biolog licens applic sbla keytruda
monotherapi first-lin treatment local advanc metastat
nsclc patient whose tumor express tumor proport score
tp without egfr genom tumor aberr sbla
base result phase trial compani submit
addit data analys fda extend pdufa date
three month april
merck astrazeneca announc fda approv lynparza use
mainten treatment adult patient deleteri suspect
deleteri germlin somat brca-mut gbrcam sbrcam
advanc epitheli ovarian fallopian tube primari periton cancer
complet partial respons first-lin platinum-bas
chemotherapi first regulatori approv parp inhibitor
first-lin mainten set brcam advanc ovarian cancer
approv base posit result pivot phase trial
merck astrazeneca
phase
trial lynparza
patient relaps
ovarian cancer two
line treatment
merck astrazeneca announc posit result phase
trial lynparza patient relaps ovarian cancer two
line treatment
merck eisai announc result new data analys lenvima
combin keytruda three differ tumor type includ
metastat nsclc metastat melanoma metastat urotheli
carcinoma present annual meet societi
immunotherapi cancer novemb
clinic data merck phase trial anti-
tigit along preclin data
present studi monotherapi
combin keytruda treatment advanc solid tumor
merck inc announc merck exercis
option licens renam investig
monoclon antibodi agonist receptor complex
current evalu treatment nonalcohol steatohepat
nash type diabet
merck announc compani investig
pneumococc conjug vaccin receiv breakthrough therapi
design fda prevent invas pneumococc
diseas ipd caus vaccin serotyp pediatr patient week
year age also develop prevent ipd
adult
merck instituto butantan non-profit produc immuno-biolog
product brazil announc collabor develop vaccin protect
dengu viru diseas mosquito-born infect
merck announc start submiss roll biolog licens
applic fda rvsvg-zebov-gp live attenu
compani investig vaccin ebola zair diseas roll
submiss made pursuant fda breakthrough therapi
design
merck announc ec approv delstrigo doravirin lamivudin
tenofovir disoproxil fumar pifeltro doravirin treatment
merck announc fda accept review supplement new drug
applic snda seek approv pifeltro combin
antiretrovir medicin delstrigo use peopl live
switch stabl antiretrovir regimen whose viru
suppress rna copies/ml pdufa date snda
merck announc
fumar pifeltro
doravirin
treatment
clinic regulatori catalyst next month
clinic regulatori catalyst next month
infant data present cough failur hospital/specialti clinic melanoma nsclc metastat breast cancer approv merck compani inc april
tabl show pipelin product develop differ phase
guidanc conclus
revenu expect includ
neg impact foreign exchang
gaap ep expect non-gaap ep expect
 includ posit impact foreign
tax rate expect
merck deliv strong perform year growth
revenu adjust ep increas
gaap ep increas reflect charg relat
format strateg oncolog collabor eisai co ltd eisai
pharmaceut sale increas reflect growth
oncolog vaccin hospit acut care partial off-set declin
virolog loss market exclus sever product
result bolster confid merck innovation-bas strategi
key pillar oncolog vaccin anim health select hospit
specialti care product expect drive sustain growth
merck enter good momentum anticip mani
opportun afford broad differenti portfolio
revenu expect
includ neg
impact foreign
merck enter
anticip mani
opportun afford
broad
pipelin
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin compar due increas cog
revenu growth compar
oper margin increas compar due decreas
expens sg expens
net margin increas compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc april
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale merck compani inc april
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset merck compani inc april
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item merck compani inc april
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free merck compani inc april
current price-to-earnings due increas stock price price-to-earnings
volatil till may later surg due strong growth ep stock price averag
price-to-earnings expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit world wellington manag compani jp morgan america price row associ geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard washington mutual investor incom fund america spdr etf vanguard institut fund-institut vanguard specialized-health fidel american balanc ishar merck compani inc april
developmentsmerck complet tender offer acquir immun designapril known msd outsid unit state canada announc success complet cash tender offer subsidiari outstand share common stock immun design purchas price per share tender offer expir share common stock immun design validli tender withdrawn tender offer repres outstand common stock immun design fulli dilut basi share accept payment accord term tender offer merck expect promptli pay share merck complet acquisit antelliq corpor becom leader emerg digit technolog livestock companion animalsapril known msd outsid unit state canada announc complet acquisit antelliq corpor fund advis bc partner today announc posit compani global leader anim health digit track traceabl monitor technolog complement exist portfolio vaccin pharmaceut antelliq oper unit within merck anim health european commiss approv merck keytruda pembrolizumab combin chemotherapi first-lin treatment adult metastat squamou non-smal cell lung cancer nsclc march known msd outsid unit state canada announc european commiss approv keytruda compani therapi combin carboplatin either paclitaxel nab-paclitaxel first-lin treatment adult metastat squamou non-smal cell lung cancer nsclc approv base data phase trial demonstr keytruda combin chemotherapi significantli improv overal surviv os adult metastat squamou nsclc regardless tumor express statu reduc risk death compar chemotherapi alon ci provid updat phase studi keytruda pembrolizumab previous treat patient advanc hepatocellular carcinomafebruari known msd outsid unit state canada announc pivot phase trial evalu keytruda merck therapi plu best support care treatment patient advanc hepatocellular carcinoma previous treat system therapi meet co-primari endpoint overal surviv os progression-fre surviv compar placebo plu best support care merck compani inc april
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
gross margin ttm
industri
averag
roa roe roi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc april
consensu view analyst trend stock
forecast
lower
forward price-to-earnings
lower
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonmrkindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate merck compani inc april
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price volatil till februari later show upward trend quarter
stock surg april given return period
stock price show upward trend year surg
rang stock gave return year
stock price volatil till april later surg year stock gave return
merck deliv strong result year growth revenu growth due strong
perform across busi recommend buy rate stock base perform
period tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
